甲睾酮联合亮丙瑞林对子宫肌瘤患者的临床疗效及血清EGF、MMP-9、Ang-2水平的影响

Clinical efficacy of methyltestosterone combined with leuprorelin in patients with uterine myoma and its effect on serum EGF,MMP-9,Ang-2 levels

目的探讨将甲睾酮与亮丙瑞林联合用于治疗子宫肌瘤患者的临床疗效及对其血清EGF、MMP-9、Ang-2水平的影响。方法选取2017年4月至2019年4月本院收治的116例子宫肌瘤患者为研究对象,按照电脑双盲法分为对照组(n=58)、观察组(n=58),对照组给予亮丙瑞林治疗,观察组接受亮丙瑞林联合甲睾酮治疗。比较两组治疗效果,血清EGF、MMP-9、Ang-2水平,不良反应。结果治疗后,与对照组相比较,观察组治疗总有效率较高(98.28%比84.48%),观察组血清EGF、MMP-9、Ang-2水平较低,差异有统计学意义(P<0.05);观察组不良反应发生率略高于对照组(10.34%比6.90%),但差异无统计学意义(P>0.05)。结论将甲睾酮与亮丙瑞林联合用于治疗子宫肌瘤患者,能够显著提高临床治疗效果,降低血清EGF、MMP-9、Ang-2水平,虽不良反应发生率略高,但患者均可耐受。

Objective To investigate the clinical effect of methyltestosterone combined with leuprorelin in the treatment of uterine myoma and its effect on serum EGF,MMP-9,Ang-2 levels.Methods 116 patients with uterine myoma treated in our hospital from April 2017 to April 2019 were divided into observation group(n=58)and control group(n=58).The control group was treated with leuprorelin,and the observation group was treated with leuprorelin combined with methyltestosterone.The therapeutic effect,serum EGF,MMP-9,Ang-2 levels,and adverse reactions were compared between the two groups.Results After the treatment,the total effective rate in the observation group was higher than that in the control group(98.28%vs.84.48%),and the levels of EGF,MMP-9,and Ang-2 in the observation group were lower,with statistically significant differences(P<0.05).The incidence of adverse reactions in the observation group was slightly higher than that in the control group(10.34%vs.6.90%),without statistically significant differences(P>0.05).Conclusion Methyltestosterone combined with leuprorelin in the treatment of patients with uterine myoma could significantly improve the effect of clinical treatment,reduce the levels of EGF,MMP-9,and Ang-2 in serum.The incidence was slightly higher,but the patients were well tolerated.